ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib

BACKGROUND: Several clinical trials have demonstrated the efficacy and safety of osimertinib in advanced non-small-cell lung cancer (NSCLC). However, there is significant unexplained variability in treatment outcome. METHODS: Observational prospective cohort of 22 pre-treated patients with stage IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Romero, Atocha, Serna-Blasco, Roberto, Alfaro, Cristina, Sánchez-Herrero, Estela, Barquín, Miguel, Turpin, María Carmen, Chico, Sofía, Sanz-Moreno, Sandra, Rodrigez-Festa, Alejandro, Laza-Briviesca, Raquel, Cruz-Bermudez, Alberto, Calvo, Virginia, Royuela, Ana, Provencio, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354150/
https://www.ncbi.nlm.nih.gov/pubmed/32676317
http://dx.doi.org/10.21037/tlcr.2020.04.01

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354150/
https://www.ncbi.nlm.nih.gov/pubmed/32676317
http://dx.doi.org/10.21037/tlcr.2020.04.01

Ejemplares similares